1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Influenza B Infections - Pipeline Review, H1 2016

Influenza B Infections - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 83 pages

Influenza B Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Influenza B Infections - Pipeline Review, H1 2016’, provides an overview of the Influenza B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza B Infections
- The report reviews pipeline therapeutics for Influenza B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Influenza B Infections therapeutics and enlists all their major and minor projects
- The report assesses Influenza B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Influenza B Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Influenza B Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Influenza B Infections - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Influenza B Infections Overview 9
Therapeutics Development 10
Pipeline Products for Influenza B Infections - Overview 10
Pipeline Products for Influenza B Infections - Comparative Analysis 11
Influenza B Infections - Therapeutics under Development by Companies 12
Influenza B Infections - Therapeutics under Investigation by Universities/Institutes 14
Influenza B Infections - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Influenza B Infections - Products under Development by Companies 18
Influenza B Infections - Products under Investigation by Universities/Institutes 19
Influenza B Infections - Companies Involved in Therapeutics Development 20
Altravax, Inc. 20
Aphios Corporation 21
Chimerix, Inc. 22
ContraFect Corporation 23
Crucell N.V. 24
CSL Limited 25
Genentech, Inc. 26
Hanmi Pharmaceuticals, Co. Ltd. 27
Humabs BioMed SA 28
Medicago Inc. 29
MedImmune, LLC 30
Mucosis B.V. 31
Novavax, Inc. 32
Sanofi Pasteur SA 33
Vaxart, Inc. 34
Zydus Cadila Healthcare Limited 35
Influenza B Infections - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
AL-18 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
APP-0205 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
APP-309 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
CF-403 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
CR-8033 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
CR-8071 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
CR-9114 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
FluGEM - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
influenza [serotype B] vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
influenza [serotypes A, B] (split virion, tetravalent) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Monoclonal Antibody for Influenza B Infections - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
oseltamivir phosphate - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
RG-6024 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
Small Molecules for Influenza B - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
VXABYW-10 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
Influenza B Infections - Recent Pipeline Updates 74
Influenza B Infections - Dormant Projects 79
Influenza B Infections - Product Development Milestones 80
Featured News and Press Releases 80
Dec 17, 2015: Vaxart Announces Enrollment of First Patient in Influenza B Phase 1 Trial 80
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine 81
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Influenza B Infections, H1 2016 10
Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Influenza B Infections - Pipeline by Altravax, Inc., H1 2016 20
Influenza B Infections - Pipeline by Aphios Corporation, H1 2016 21
Influenza B Infections - Pipeline by Chimerix, Inc., H1 2016 22
Influenza B Infections - Pipeline by ContraFect Corporation, H1 2016 23
Influenza B Infections - Pipeline by Crucell N.V., H1 2016 24
Influenza B Infections - Pipeline by CSL Limited, H1 2016 25
Influenza B Infections - Pipeline by Genentech, Inc., H1 2016 26
Influenza B Infections - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 27
Influenza B Infections - Pipeline by Humabs BioMed SA, H1 2016 28
Influenza B Infections - Pipeline by Medicago Inc., H1 2016 29
Influenza B Infections - Pipeline by MedImmune, LLC, H1 2016 30
Influenza B Infections - Pipeline by Mucosis B.V., H1 2016 31
Influenza B Infections - Pipeline by Novavax, Inc., H1 2016 32
Influenza B Infections - Pipeline by Sanofi Pasteur SA, H1 2016 33
Influenza B Infections - Pipeline by Vaxart, Inc., H1 2016 34
Influenza B Infections - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Influenza B Infections Therapeutics - Recent Pipeline Updates, H1 2016 74
Influenza B Infections - Dormant Projects, H1 2016 79

List of Figures
Number of Products under Development for Influenza B Infections, H1 2016 10
Number of Products under Development for Influenza B Infections - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Targets, H1 2016 38
Number of Products by Stage and Targets, H1 2016 38
Number of Products by Mechanism of Actions, H1 2016 40
Number of Products by Stage and Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Routes of Administration, H1 2016 42
Number of Products by Molecule Types, H1 2016 44
Number of Products by Stage and Molecule Types, H1 2016 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Influenza
Therapy
Vaccine

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.